Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Abdulrahman Al Shaya"'
Autor:
Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B Korayem, Aisha Alharbi, Ali F. Altebainawi, Shatha A. Aldkheel, Sarah G. Alotaibi, Ramesh Vishwakarma, Hanan Alshareef, Samiah Alsohimi, Mashael AlFaifi, Abdulrahman Al Shaya, Haifa A. Alhaidal, Raghad M. Alsubaie, Hessah Alrashidi, Khalid J. Albarqi, Dalal T. Alangari, Reem M. Alanazi, Noora M. Altaher, Hasan M. Al-Dorzi
Publikováno v:
Renal Failure, Vol 45, Iss 2 (2023)
Tocilizumab (TCZ) is recommended in patients with COVID-19 who require oxygen therapy or ventilatory support. Despite the wide use of TCZ, little is known about its safety and effectiveness in patients with COVID-19 and renal impairment. Therefore, t
Externí odkaz:
https://doaj.org/article/ca2f1083e62d4c88939688b4397622d0
Autor:
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Shmeylan Al Harbi, Abdulrahman Al Shaya, Hisham A. Badreldin, Raed Kensara, Abdullah F. Alharthi, Jahad Alghamdi, Ahad Alawad, Rand Alotaibi, Abdullah Kharbosh, Hessa Al Muqati, Abdulmohsen Alhuwahmel, Mohammed Almusallam, Ghada Albarrak, Ibrahim Al Sulaihim, Bader Alanazi, Bodoor S. Al-Dosari, Ramesh Vishwakarma, Alawi S. Alsaeedi, Ghassan Al Ghamdi, Hadeel Alkofide, Hasan M. Al-Dorzi
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
BackgroundThe cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Reductase Inhibitors (statins) are known to have plei
Externí odkaz:
https://doaj.org/article/497e868d0a4c41eabcb9464903f68d69
Autor:
Khalid Al Sulaiman, Mashael Al Mutairi, Omar Al Harbi, Alanoud Al Duraihim, Sara Aldosary, Haifa Al Khalil, Abdulrahman Al Shaya, Shmeylan Al Harbi, Nouf Alotaibi, Kholoud Al Aamer, Ramesh Vishwakarma, Mohammed Al Asiri, Ohoud Aljuhani, Abdulmalik Al Katheri, Abdulkareem M. Al Bekairy
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Background Using vitamin K for correction of coagulopathy in critically ill patients is controversial with limited evidence. This study aims to evaluate the efficacy and safety of vitamin K in the correction of international normalized ratio (INR) el
Externí odkaz:
https://doaj.org/article/0d4647e9cbd54c529725b3bec9aa442a
Autor:
Abdulmalik Alkatheri, Abdulkareem Al Bekairy, Salah Aburuz, Amjad Qandil, Nabil Khalidi, Khalid Abdullah, Sayyari Al Sayyari, Rami Bustami, Shmeylan Al Harbi, Sultan Al Raddadi, Khalifah Al Thiab, Khalid Bin Saleh, Abdulrahman Al Shaya
Publikováno v:
Annals of Saudi Medicine, Vol 35, Iss 5, Pp 368-376 (2015)
BACKGROUND AND OBJECTIVES: Despite the worldwide recognition of the importance of quality of life (QOL) assessment, research data on QOL for renal and liver transplant recipients are limited. The main objective of this study was to explore and compar
Externí odkaz:
https://doaj.org/article/b0fc99abc85648f997d2e0a0689acb2e
Autor:
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Shmeylan Al Harbi, Abdulrahman Al Shaya, Hisham A. Badreldin, Raed Kensara, Abdullah Al Harthi, Jahad Alghamdi, Ahad Alawad, Rand Alotaibi, Abdullah Kharbosh, Hessa Al Muqati, Abdulmohsen Alhuwahmel, Mohammed Almusallam, Ghada Albarrak, Ibrahim Al Sulaihim, Bader Alanazi, Bodoor S. Al-Dosari, Ramesh Vishwakarma, Alawi S. Alsaeedi, Ghassan Al Ghamdi, Hasan M Al-Dorzi
Background The cardiovascular complications of Severe Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. Statins are known to have pleiotropic and anti-inflam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95aa4aafaf963ac55c2e8fa22f624d44
https://doi.org/10.21203/rs.3.rs-828175/v3
https://doi.org/10.21203/rs.3.rs-828175/v3
Autor:
Shmeylan Al Harbi, Khalid Eljaaly, Haytham Noureldeen, Adel Alshabasy, Abdullah M Alhammad, Ohoud Aljuhani, Amina Alkhalaf, Bodoor Al Dosari, Mohammed Aboudeif, Ramesh Vishwakarma, Khalid Al Sulaiman, Hisham A. Badreldin, Ghazwa B. Korayem, Abdulrahman Al Shaya, Muneera M. Aleissa
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (COVID-19)
Autor:
Abdulrahman Al Shaya, Abdullah Al Harthi, Ohoud Aljuhani, Bodoor S. Al-Dosari, Ramesh Vishwakarma, Abdulmohsen Alhuwahmel, Ghazwa B. Korayem, Jahad Alghamdi, Hisham A. Badreldin, Bader Alanazi, Khalid Al Sulaiman, Ghassan Al Ghamdi, Ibrahim Al Sulaihim, Hasan M. Al-Dorzi, Ali F. Altebainawi, Mohammed Almusallam, Hessa Al Muqati, Rand Alotaibi, Shmeylan Al Harbi, Alawi S. Alsaeedi, Ahad Alawad, Raed Kensara, Abdullah Kharbosh
Purpose The complications of Severe Corona Virus Disease 2019 (COVID-19) are attributed to the overproduction of early response proinflammatory cytokines, causing a systemic hyperinflammatory state. Statins are potentially a potent adjuvant therapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9bf8cfdd74f2185bc0cc97bb860231
https://doi.org/10.21203/rs.3.rs-828175/v2
https://doi.org/10.21203/rs.3.rs-828175/v2
Autor:
Ramesh Vishwakarma, Alhomaidi Al Guwairy, Raed Kensara, Khalid Al Sulaiman, Shmeylan Al Harbi, Rahmah Algarni, Aisha Alharbi, Ohoud Aljuhani, Abdulrahman Al Shaya, Abdullah Kharbosh, Ghazwa B. Korayem
Publikováno v:
Critical Care
Critical Care, Vol 25, Iss 1, Pp 1-8 (2021)
Critical Care, Vol 25, Iss 1, Pp 1-8 (2021)
Background: Zinc is a trace element that plays a role in stimulating innate and acquired immunity. The role of zinc in critically ill patients with COVID-19 remains unclear. This study aims to evaluate the efficacy and safety of zinc sulfate as adjun
Autor:
Ghazwa B. Korayem, Amina Alkhalaf, Ohoud Aljuhani, Bodoor Al Dosari, Khalid Al Sulaiman, Muneera M. Aleissa, Ramesh Vishwakarma, Abdulrahman Al Shaya, Hyatham Albossiry, Adel Alshabasy, Shmeylan Al Harbi, Mohammed Abodeif, Hisham A. Badreldin, Abdullah M Alhammad, Khalid Eljaaly
Background:Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits IL-6 receptor. Several randomized clinical trials (RCTs) have evaluated tocilizumab’s safety and efficacy in patients with COVID-19. These stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f57e8058ed6ffe479d837dd9b1c9d392
https://doi.org/10.21203/rs.3.rs-469073/v1
https://doi.org/10.21203/rs.3.rs-469073/v1
Autor:
Khalid Alsulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali Altebainawi, Abdulrahman Al Shaya, Hisham Badreldin, Abdullah Al Harthi, Abdulrahman Alissa, Ramesh Vishwakarma, Raed Kensara
Publikováno v:
Critical Care Medicine. 50:84-84